Skip to main content

Table 2 Risk ratios of contralateral breast cancer associated with different aspects of tamoxifen use

From: Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study

Use of tamoxifen

CBC cases

UBC controls

RRa (95 % CI)

P value

P het.

N (%)

N (%)

Tamoxifen use

     

 Never

1054 (69)

1425 (64)

1.0 (Referent)

  

 Ever

467 (31)

787 (36)

0.76 (0.63–0.92)

  

Tamoxifen use according to time since first breast cancer

     

 1–4 years

     

  Never

423 (72)

644 (65)

1.0 (Referent)

  

  Ever

163 (28)

342 (35)

0.67 (0.51–0.88)

  

 5–9 years

     

  Never

387 (67)

504 (63)

1.0 (Referent)

  

  Ever

187 (33)

300 (37)

0.76 (0.57–1.03)

 

0.3

 ≥10 years

     

  Never

244 (68)

277 (66)

1.0 (Referent)

  

  Ever

117 (32)

145 (34)

0.95 (0.67–1.34)

  

Mean duration of tamoxifen (months)

40.2

40.5

 

0.8

 

Median duration of tamoxifen (months)

44

43

 

0.6

 

 Interquartile range (months)

20–60

18–60

   

 Range (months)

>0–106

>0–174

   

Duration of tamoxifen use

     

 Never

1054 (69)

1425 (64)

1.0 (Referent)

  

 ≤18 months

92 (6)

165 (7)

0.90 (0.65–1.24)

  

 19–53 months

139 (9)

242 (11)

0.76 (0.57–1.00)

0.7e

 

 ≥54 months

167 (11)

244 (11)

0.80 (0.61–1.04)

  

 Unknownb

69 (5)

136 (6)

   

Mean time since last use at reference date for past users (months)

57.1

45.2

 

0.0001

 

Median time since last use at reference date for past users (months)

48

37

 

0.0001

 

 Interquartile range (months)

24–83

13–65

   

 Range (months)

1–204

1–186

   

Time since last tamoxifen use at reference datec

     

 Never

1054 (69)

1425 (64)

1.0 (Referent)

  

 Current use, 0 months since last used

131 (9)

249 (11)

0.73 (0.55–0.97)

  

 Past use, <37 months since last use

110 (7)

206 (9)

0.73 (0.53–1.00)

0.2e

 

 Past use, ≥37 months since last use

161 (11)

208 (9)

0.98 (0.73–1.31)

  

 Unknownb

65 (4)

124 (6)

   

Time since last tamoxifen use at reference date according to duration of use

     

 Never

1054 (69)

1425 (64)

1.0 (Referent)

  

 <54 months duration

     

  Current used

101 (7)

178 (8)

0.86 (0.62–1.19)

  

  Past use, <37 months since last use

53 (3)

112 (5)

0.71 (0.47–1.07)

  

  Past use, ≥37 months since last use

77 (5)

117 (5)

0.82 (0.56–1.19)

  

 ≥54 months duration

   

0.01e

 

  Current used

28 (2)

69 (3)

0.44 (0.27–0.73)

  

  Past use, <37 months since last use

56 (4)

90 (4)

0.71 (0.45–1.12)

  

  Past use, ≥37 months since last use

83 (5)

85 (4)

1.25 (0.84–1.86)

  

  Unknown durationb

69 (5)

136 (6)

   
  1. aAdjusted for age at first breast cancer diagnosis (continuous), first-degree family history of breast cancer (yes, no, unknown), histology (lobular, other, unknown), stage (local, regional, unknown), and estrogen receptor/progesterone receptor status (positive for either, negative, unknown) at first diagnosis, radiation (yes, no), chemotherapy (yes, no), and other endocrine therapy (yes, no)
  2. bUnknown not included in model
  3. cCut-point at median for values greater than 0 months in WECARE I and II controls
  4. dCurrent users of tamoxifen at reference date
  5. eOverall P-value
  6. CBC contralateral breast cancer, CI confidence intervals, P-het. P value for heterogeneity, RR risk ratio, UBC unilateral breast cancer